Unique café beneath iconic Glasgow landmark hits the market after eight years
The Glasgow city centre café has hit the market (Image: BusinessesForSale.com)
A unique café and takeaway in the heart of Glasgow has hit the market.
Café Sono, located on bustling Argyle Street directly beneath Glasgow Central Station, is on the market for £125,000.
Since opening in 2017, it has become a staple for commuters, locals, and late-night visitors.
(Image: BusinessesForSale.com)
READ MORE: Tributes pour in for murdered ex-football starlet as fundraiser raises huge amount
Operating as a café by day and a hot food takeaway in the evening, the business benefits from late-night food consent until 4am, capitalising on heavy footfall and weekend nightlife.
Its standout location — across from one of the main entrances to Glasgow Central and under the iconic Hielanman's Umbrella — sees thousands of passersby daily.
ADVERTISEMENT
(Image: BusinessesForSale.com)
The café is being sold with two separate units, offering flexibility and potential for expansion or subletting.
The combined leasehold rent is £39,600 per annum or £19,800 per unit.
READ MORE: Retail giant reveals opening date new Glasgow store
(Image: BusinessesForSale.com)
Currently generating an average weekly turnover of £8,000 to £9,000, Café Sono is known for its high-quality hot dogs, burgers, and kebabs.
Café Sono features rustic, character-filled décor and operates seven days a week, from noon to midnight, and until 4am on weekends.
It's currently run by the owner, who is selling to focus on another business outside the city.
With upcoming Glasgow City Council renovations planned for the underpass area, foot traffic and visibility are expected to increase further, making this an even more attractive investment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
3000 jobs cut in $12 billion wipeout
Australia's largest pharmaceutical company could cut nearly 3000 jobs from its workforce as it looks to reduce its headcount across a number of businesses. The biggest shake up of the business in decades will see nearly 15 per cent of the global workforce reduced in a move aimed at 'simplifying the business.' Currently CSL employs about 30,000 staff globally. CSL said the one-off restructure would cost the business $770m pre tax before saving $500 to $550m over the next three years. The business said it would use these savings to invest in 'high priority' opportunities. Its share price dropped 11.15 per cent off the back of Tuesday morning's news — wiping roughly $12 billion off the company's market cap. CSL also announced its intention to demerge its influenza prevention vaccines-focused unit known as Seqirus into a separate ASX listed business in 2026. Gordon Naylor, a former president of CSL Seqirus, will run the new business. It will also combine the commercial and medical operations of its core blood plasma and iron deficiency businesses into one unit. The remaining CSL group will continue to have positions in multiple rare and serious diseases. The demerger will be subject to third party consents, regulatory approvals and CSL will conduct a voluntary shareholder vote. It has been tough 12 months for CSL, with the business facing unpredictable tariffs on its exports to the United States. On August 6 US President Donald Trump announced the first 'small tariff' on foreign-made drugs. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, one-and-a-half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent. Mr Trump said he is lifting prices as he wants to make American drugs cheaper for locals. CSL on Tuesday announced a 14 per cent increase in full-year underlying profits, up to $US3.3bn ($5.1bn) which was at the top of its forecasts. eToro market analyst Josh Gilbert said while the restructing comes with a sizeable one off cost, the move is expected to sharpen the group's focus on its high-growth plasma and kidney care business. 'For investors, the view here is that CSL is trying to create a clearer business structure and improve investor returns. However, markets hate uncertainty, and this shake-up brings plenty of it,' he said. 'These are huge changes that come with execution risk, and in my view, the market will react poorly to the news short term.' Mr Gilbert said CSL overall delivered a 'solid' full-year result with net profit ahead of expectations. 'But the real headline isn't the profit beat, it's the sweeping shake-up announced alongside it. As part of a major reset, CSL will reduce its workforce by around 15 per cent, close underperforming plasma centres, and spin off its Seqirus vaccine arm to list separately on the ASX by the end of the fiscal year,' he said. CSL chief executive officer Paul McKenzie said the business recognises a dynamic global backdrop, competitive pressure and organisation complexity have challenged CSL and hindered its ability to deliver superior returns. 'CSL Seqirus continued to show the resilience of its differentiated portfolio and platforms by generating growth in a challenging environment,' he said. 'The majority of avian flu contracts globally were awarded to CSL Seqirus, which was strong recognition of our best-in-class, differentiated platforms.'
Wall Street Journal
6 hours ago
- Wall Street Journal
How an Obscure Firm Bet on the Trumps and Became Their Go-To Dealmaker
In order to become a trusted financial partner of the world's most powerful family, it helps to buy low. That partly explains how a tiny onetime biotech firm with nearly a quarter-billion in accumulated losses transformed into something of an in-house investment bank for the Trump family's business empire, handling everything from crypto to manufacturing deals.
Yahoo
7 hours ago
- Yahoo
Microsoft Likely to Maintain Strong Momentum in Cloud, AI Growth, Truist Says
Microsoft (MSFT) is likely to maintain strong momentum in its cloud and artificial intelligence busi Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
